|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed a decline in the expression of SOX2, P16 and P27 after miR-340 over-expression, whereas we observed an increase in the expression of cyclin A2, CDK2, SOX17, P18, SMAD 4 and RB.
|
27229858 |
2017 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenomatous polyposis, ret for medullary thyroid carcinoma, p53 for the Li-Fraumeni syndrome, p16 for melanoma and RB1 for retinoblastoma.
|
11205230 |
2001 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation.
|
16401683 |
2006 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that p16 inactivation is selected as the most effective mechanism of blocking the cyclin D-Rb pathway during the evolution of an invasive cancer from precursor lesions.
|
10535995 |
1999 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At least 1 of these abnormalities was found in 86% of the cases and a positive correlation was noted between p16 and pRb (P = 0.009).
|
18484097 |
2008 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies on Radiation Therapy Oncology Group tissue samples have identified aberrant expression of p53, MDM2 (an E3 ubiquitin ligase that targets p53 for proteosomal degradation), and p16 (an upstream regulator of retinoblastoma and hence E2F1 in prostate cancer); abnormal expression of these biomarkers has been associated with clinical outcome after radiotherapy ± androgen deprivation therapy.
|
20832018 |
2010 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The growth suppressing activity of the retinoblastoma suspectibility gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose kinase activity is negatively regulated by CDK inhibitors of the p16 family.
|
8570224 |
1996 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the TBP-2-overexpressing cells, a G1 arrest was observed in association with an increase of p16 expression and reduction of retinoblastoma phosphorylation.
|
14983878 |
2004 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VRK1 protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16.
|
16547155 |
2006 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gene and protein transfer experiments demonstrated that concurrent alterations of cyclin D1 and p16 levels cooperate to (de)regulate G1 control in diploid fibroblasts, and that both events influence growth of retinoblastoma (RB)-positive, but not RB-deficient cancer cells.
|
7585513 |
1995 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genes most commonly associated with the process of oncogenesis include: p53 inactivating mutation; hDM2 overexpression; p16 reduced expression; K-/H-RAS activating mutation; PTEN inactivating mutation/deletion; EGFR activating mutation and overexpression; retinoblastoma inactivating mutation and deletion; Cyclin proteins overexpression; CD95 reduced expression; protective BCL-2 proteins overexpression; to name but just a few of such molecules.
|
23974512 |
2013 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate survival analysis revealed that the gene amplification of c-Myc (p = 0.008), Mdm2 (p = 0.020) and the gene deletion of p21 (p = 0.004), p16 (p = 0.015), and Rb1 (p = 0.028) were the independent predictive factor of 5-year OS for patients with TNBC.
|
24096545 |
2014 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).
|
10732752 |
2000 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coexisting intraepithelial carcinoma was detected in seven NECs and only one lesion showed the combination of diffuse RB loss and p16 overexpression.
|
30952735 |
2019 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we reported that loss of p16 expression rather than loss of Rb occurs in most human pituitary adenomas.
|
9290697 |
1997 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inverse relationship between p16 and Rb was 62.5% (5/8).
|
17549378 |
2007 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inverse correlation of Rb and p16 defects in certain human tumors has led us to investigate the expression of p16 in human pituitary tumors as an indirect mechanism of Rb inactivation.
|
8653683 |
1996 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p16 gene expresses two alternative transcripts (p16alpha and p16beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways.
|
10498902 |
1999 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong immunoreactivity for p16 protein was observed in both nuclei and cytoplasm of the tumor cells in eight out of nine cases of eccrine porocarcinomas, while RB expression was negative in these cases.
|
12207741 |
2002 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p16 protein transcriptionally inhibits expression of retinoblastoma tumor-suppressor gene pRB.
|
11792751 |
2002 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the expression of RB and p16 protein was examined by Western blot analysis.
|
8674005 |
1996 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression levels of the p16, p15, p14, and retinoblastoma-susceptibility (RB) genes in primary prostate cancers and human prostate cancer cell lines, and correlated this with the DNA methylation levels of two loci in p16.
|
10797499 |
2000 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The second set of genetic alterations are etiological nonspecific, it includes recurrent gains and losses of chromosomes, alteration of TP53 gene, activation of WNT/beta-catenin pathway through CTNNB1/beta-catenin and AXIN (axis inhibition protein) mutations, inactivation of retinoblastoma and IGF2R (insulin-like growth factor 2 receptor) pathways through inactivation of RB1 (retinoblastoma 1), P16 and IGF2R.
|
16799619 |
2006 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The protein and mRNA expressions of cyclin D1, proliferating cell nuclear antigen (PCNA), retinoblastoma (Rb), and p16 were observed with immunofluorescence and RT-PCR, respectively.
|
22139542 |
2011 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p16 gene regulates cyclin D1-CDK4 activity and prevents retinoblastoma tumor suppressor gene phosphorylation, thereby downregulating cellular proliferation.
|
12148857 |
2002 |